RICHMOND, Calif., Jan. 13, 2021 (Globe NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an sector chief in exoskeleton know-how for professional medical and industrial use, now declared preliminary major line economical benefits for the fourth quarter and fiscal calendar year ended December 31, 2020.
Whole income for the fourth quarter of 2020 is an approximated $2.3 million, when compared to total revenue of $3.7 million in the fourth quarter of 2019. Whole earnings for fiscal yr 2020 is believed to be close to $8.9 million, as opposed to $13.9 million in 2019.
Hard cash at December 31, 2020 was $12.9 million, in comparison to $10.9 million at December 31, 2019.
“Our believed fourth quarter 2020 profits mirrored strong efficiency as we executed on key initiatives although navigating by way of COVID-related marketplace difficulties,” commented Jack Peurach, President and Main Govt Officer of Ekso Bionics. “During the quarter, we ongoing to achieve traction with our network operator tactic in the health care company. We feel that our new subscription product, which cuts down funds constraints, will facilitate further strategic deals and even more increase our set up base in 2021. We are also pleased that our latest industrial innovation, EVO™, created robust purchaser excitement and strong original adoption trends pursuing its August 2020 launch. Seeking in advance, we remain confident that as the COVID predicament improves, our escalating pipeline of options will develop better momentum supported by our compelling benefit propositions in both equally the professional medical and industrial fronts.”
The expected effects talked over in this press release are centered on management’s preliminary, unaudited investigation of monetary effects for the period and 12 months ended December 31, 2020. As of the day of this push launch, the Firm has not completed its economic statement reporting course of action for the time period and year ended December 31, 2020, and the Company’s independent registered accounting firm has not audited the preliminary money info discussed in this push release. In the course of the class of the Company’s quarter-end closing processes and critique method, the Company may perhaps discover goods that would require it to make adjustments, which may be material to the information offered higher than. As a consequence, the estimates above constitute ahead-seeking facts and are matter to pitfalls and uncertainties, like attainable adjustments to preliminary running final results. The Firm expects to report finish fourth quarter and whole calendar year 2020 economic benefits throughout the last week of February 2021.
About Ekso Bionics®
Ekso Bionics® is a main developer of exoskeleton answers that amplify human probable by supporting or maximizing power, stamina and mobility across professional medical and industrial applications. Established in 2005, the Firm continues to develop on its market-major experience to style some of the most slicing-edge, ground breaking wearable robots readily available on the current market. Ekso Bionics is the only exoskeleton firm to give technologies that vary from assisting all those with paralysis to stand up and stroll, to enhancing human abilities on position web-sites across the world. The Firm is headquartered in the San Francisco Bay Space and is stated on the Nasdaq Cash Current market underneath the image “EKSO.” For additional facts, take a look at: www.eksobionics.com or stick to @EksoBionics on Twitter.
Any statements contained in this push release that do not describe historical details may well represent forward-on the lookout statements. Forward-looking statements may possibly contain, without limitation, statements concerning (i) the programs and targets of management for long run operations, including plans or goals relating to the layout, advancement and commercialization of human exoskeletons, options or technique relating to the internet marketing and adoption and acceptance of the Company’s products and probable for adoption of the Company’s items by the marketplace, (ii) estimates or projection of monetary benefits, money issue, money expenses, money construction or other fiscal objects, (iii) the Company’s long run monetary effectiveness and (iv) the assumptions fundamental or relating to any assertion described in details (i), (ii) or (iii) over. These types of ahead-searching statements are not intended to predict or promise actual effects, effectiveness, events or instances and could not be understood simply because they are centered upon the Company’s existing projections, options, targets, beliefs, anticipations, estimates and assumptions and are subject matter to a variety of hazards and uncertainties and other influences, numerous of which the Organization has no regulate about. Precise success and the timing of selected activities and conditions could vary materially from all those explained by the forward-wanting statements as a final result of these threats and uncertainties. Components that could influence or add to the inaccuracy of the ahead-hunting statements or induce genuine outcomes to differ materially from predicted or wished-for effects could incorporate, with out limitation, adjustments ensuing from the Company’s finalization of its financial statements for and as of the period of time and 12 months ended December 31, 2020, information or new modifications in points or instances that could manifest prior to the submitting of the Company’s Yearly Report on Sort 10-K for the 12 months finished December 31, 2020 that are needed to be bundled in these types of once-a-year report, the Company’s incapability to attain enough funding to fund the Company’s functions and essential to develop or increase our technological innovation, the considerable size of time and assets connected with the development of the Company’s products and solutions, the Company’s failure to reach broad sector acceptance of the Company’s goods, the failure of our gross sales and marketing group or associates to market our solutions efficiently, adverse outcomes in upcoming medical experiments of the Company’s professional medical product goods, the failure to get hold of or sustain patent safety for the Company’s technologies, failure to get hold of or sustain regulatory approval to market place the Company’s medical gadgets, absence of product diversification, existing or enhanced levels of competition, the Company’s failure to employ the Company’s business options or approaches and the impression of the COVID-19 pandemic. These and other factors are discovered and explained in a lot more detail in the Company’s filings with the SEC. To master much more about Ekso Bionics make sure you go to us at www.eksobionics.com or refer to our Twitter web site at @EksoBionics. The Organization does not undertake to update these ahead-looking statements.